Long-term safety of pirtobrutinib in people with blood cancers
Tests long-term safety of pirtobrutinib in adults with chronic lymphocytic leukemia or lymphoma.
Plain-language title generated from the registry record
Registry title: A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Key facts
- Where
- Adelaide, Melbourne, and Victoria, AustraliaSee the 3 sites
- Phase
- Phase 4
Where in Australia
- Flinders Medical CentreAdelaide, AustraliaTaking people
- Peter MacCallum Cancer CentreMelbourne, AustraliaNo longer taking part
- Linear Clinical ResearchVictoria, AustraliaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06876662
- Record updated
- 2 March 2026
- Original description
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.Read full original descriptionShow less
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Inclusion: Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are:; receiving study intervention; in the short-term follow-up period, or; in the long-term follow-up period.
Exclusion: Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001.